MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$303,647K
Free Cash flow
-$57,237K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Acquired in-process research and...
Proceeds from the issuance of co...
Others
Negative Cash Flow Breakdown
Purchases of investments
Payments of milestones achieved ...
Payments of debt issuance costs ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-111,456
-80,987
-240,442
-51,499
Acquired in-process research and development
30,000
-
166,672
5,000
Depreciation expense
4
6
10
11
Loss on disposal of property and equipment
-
-
0
0
Net amortization of premiums and accretion of discounts on investments
-1,287
-110
-421
-193
Non-cash interest expense on royalty obligation
6,837
6,263
5,648
1,679
Non-cash interest expense on senior secured term loan
2,054
34
-
-
Non-cash interest expense on convertible senior notes
280
-
-
-
Stock-based compensation expense
8,619
9,195
7,580
7,336
Non-cash lease expense
269
264
224
205
Prepaid expenses and other assets
-1,109
6,482
2,357
1,601
Accounts payable
-1,334
1,795
1,116
-1,954
Accrued expenses
7,938
-4,963
9,801
102
Operating lease liabilities
-270
-211
-245
-211
Net cash used in operating activities
-57,237
-75,196
-52,414
-41,125
Purchases of property and equipment
0
2
0
0
Purchases of investments
331,810
76,520
132,893
59,195
Proceeds from sales and maturities of investments
74,106
108,133
69,529
104,238
Product candidate license acquisitions
-
-
30,000
5,000
Payments of milestones achieved pursuant to license agreements
30,000
-
-
-
Net cash used in investing activities
-287,704
31,611
-93,364
40,043
Payment of deferred offering costs
-
-
-
3,324
Payment of agent fees and offering costs-Private Placement And At Offering
-
-
12,665
-
Payments of other offering costs for the atm offering-At Market Offering
-
38
-
-
Payments of other offering costs for the atm offering and equity offering
527
-
-
-
Proceeds from royalty obligation
-
-
0
75,000
Payments of debt issuance costs for the senior secured term loan and convertible senior notes
1,460
474
-
-
Proceeds from exercise of stock options
806
367
1,611
664
Proceeds from issuance of common stock under employee stock purchase plan
0
592
0
276
Proceeds from issuance of common stock-Private Placement
-
-
120,000
-
Proceeds from issuance of common stock, net of commissions-At Market Offering
0
71,532
28,573
-
Proceeds from issuance of common stock, net of commissions-Equity Offering
14,100
94,000
-
-
Proceeds from senior secured term loan, net of discount
0
73,500
-
-
Proceeds from the issuance of convertible senior notes, inclusive of underwriters' exercise of the overallotment option in full, net of commissions
29,100
194,000
-
-
Net cash provided by financing activities
42,057
433,479
140,843
72,616
Effect of exchange rate changes on cash and cash equivalents
-763
-311
11
25
Net increase (decrease) in cash and cash equivalents
-303,647
389,583
-4,924
71,559
Cash and cash equivalents at beginning of period
500,224
110,641
115,565
319,832
Cash and cash equivalents at end of period
196,577
500,224
110,641
115,565
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the
issuance of convertible...
$29,100K
Proceeds from issuance of
common stock, net of...
$14,100K
Proceeds from exercise of
stock options
$806K
(-55.74%↓ Y/Y)
Net cash provided by
financing activities
$42,057K
(2209.56%↑ Y/Y)
Canceled cashflow
$1,987K
Net increase
(decrease) in cash and cash...
-$303,647K
(-10.09%↓ Y/Y)
Canceled cashflow
$42,057K
Proceeds from sales and
maturities of investments
$74,106K
(173.25%↑ Y/Y)
Acquired in-process
research and development
$30,000K
Stock-based compensation
expense
$8,619K
(-24.60%↓ Y/Y)
Accrued expenses
$7,938K
(54.17%↑ Y/Y)
Non-cash interest
expense on royalty...
$6,837K
Non-cash interest
expense on senior...
$2,054K
Prepaid expenses and
other assets
-$1,109K
(-38.28%↓ Y/Y)
Non-cash interest
expense on convertible...
$280K
Non-cash lease expense
$269K
(-39.69%↓ Y/Y)
Depreciation expense
$4K
(-88.57%↓ Y/Y)
Payments of debt issuance
costs for the senior...
$1,460K
Payments of other
offering costs for the atm...
$527K
Net cash used in
investing activities
-$287,704K
(-44.89%↓ Y/Y)
Net cash used in
operating activities
-$57,237K
(27.36%↑ Y/Y)
Canceled cashflow
$74,106K
Canceled cashflow
$57,110K
Effect of exchange rate
changes on cash and cash...
-$763K
(-164.93%↓ Y/Y)
Purchases of investments
$331,810K
(47.04%↑ Y/Y)
Net loss
-$111,456K
(-29.91%↓ Y/Y)
Payments of milestones
achieved pursuant to...
$30,000K
Accounts payable
-$1,334K
(85.51%↑ Y/Y)
Net amortization of
premiums and accretion of...
-$1,287K
(2.28%↑ Y/Y)
Operating lease
liabilities
-$270K
(39.46%↑ Y/Y)
Buy us a coffee
Zenas BioPharma, Inc. (ZBIO)
Zenas BioPharma, Inc. (ZBIO)